AU2005309820B2 - 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol - Google Patents

2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol Download PDF

Info

Publication number
AU2005309820B2
AU2005309820B2 AU2005309820A AU2005309820A AU2005309820B2 AU 2005309820 B2 AU2005309820 B2 AU 2005309820B2 AU 2005309820 A AU2005309820 A AU 2005309820A AU 2005309820 A AU2005309820 A AU 2005309820A AU 2005309820 B2 AU2005309820 B2 AU 2005309820B2
Authority
AU
Australia
Prior art keywords
compound
biological condition
lack
hydroxy
adequate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005309820A
Other languages
English (en)
Other versions
AU2005309820A1 (en
Inventor
Margaret Clagett-Dame
Hector F. Deluca
Lori A. Plum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of AU2005309820A1 publication Critical patent/AU2005309820A1/en
Application granted granted Critical
Publication of AU2005309820B2 publication Critical patent/AU2005309820B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AU2005309820A 2004-11-22 2005-11-18 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol Ceased AU2005309820B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62995804P 2004-11-22 2004-11-22
US60/629,958 2004-11-22
PCT/US2005/041888 WO2006057915A2 (en) 2004-11-22 2005-11-18 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol

Publications (2)

Publication Number Publication Date
AU2005309820A1 AU2005309820A1 (en) 2006-06-01
AU2005309820B2 true AU2005309820B2 (en) 2011-06-23

Family

ID=36498437

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005309820A Ceased AU2005309820B2 (en) 2004-11-22 2005-11-18 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol

Country Status (11)

Country Link
US (1) US8604008B2 (cg-RX-API-DMAC7.html)
EP (1) EP1827452B1 (cg-RX-API-DMAC7.html)
JP (1) JP5036548B2 (cg-RX-API-DMAC7.html)
AT (1) ATE499942T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005309820B2 (cg-RX-API-DMAC7.html)
CA (1) CA2588063C (cg-RX-API-DMAC7.html)
DE (1) DE602005026694D1 (cg-RX-API-DMAC7.html)
ES (1) ES2358914T3 (cg-RX-API-DMAC7.html)
MX (1) MX2007006094A (cg-RX-API-DMAC7.html)
NZ (1) NZ555561A (cg-RX-API-DMAC7.html)
WO (1) WO2006057915A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ555561A (en) 2004-11-22 2009-02-28 Wisconsin Alumni Res Found 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol (a Vitamin D derivative)
JP2008520708A (ja) * 2004-11-22 2008-06-19 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１９−ノル−（２０Ｒ）−１α−ヒドロキシ−ビスホモプレグナカルシフェロール
CA2824870C (en) * 2011-06-14 2018-08-14 Wisconsin Alumni Research Foundation 3-desoxy-2-methylene-19-nor-vitamin d analogs and their uses

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0503923B1 (en) * 1991-03-11 1994-12-28 Wisconsin Alumni Research Foundation Synthesis of 1 alpha-hydroxy-secosterol compounds
WO1998041501A1 (en) * 1997-03-17 1998-09-24 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin d compounds
WO2002020021A1 (en) * 2000-09-08 2002-03-14 Wisconsin Alumni Research Foundation 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
US6566352B1 (en) * 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
WO2003051828A2 (en) * 2001-12-13 2003-06-26 Wisconsin Alumni Research Foundation (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
WO2005051323A2 (en) * 2003-11-25 2005-06-09 Wisconsin Alumni Research Foundation Vitamin d analogs for obesity prevention and treatment

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666634A (en) * 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
DE69400495T2 (de) 1993-04-05 1997-04-30 Wisconsin Alumni Res Found 19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle
US5552392A (en) * 1993-11-03 1996-09-03 Wisconsin Alumni Research Foundation Method of treating hypoparathyroidism with (20S) vitamin D compounds
US5891865A (en) * 1996-10-04 1999-04-06 Wisconsin Alumni Research Foundation Treatment of arthritic disease induced by infectious agents
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US5945410A (en) 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US5936105A (en) * 1997-06-13 1999-08-10 Tetrionics, Inc. 14-EPI-19-nor-vitamin D compounds and methods
US6835723B2 (en) * 2001-12-13 2004-12-28 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-1α-hydroxy-bis-homo-pregnacalciferol in crystalline form
US6627622B2 (en) * 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
DE60310050T2 (de) * 2002-03-29 2007-07-05 Wisconsin Alumni Research Foundation, Madison Ein verfahren zur herstellung von 1-alpha-hydroxy-2-methylen-19-nor-homopregnacalciferol
EP1656157B1 (en) * 2003-08-20 2011-12-21 Wisconsin Alumni Research Foundation 2-methylene-19-nor-vitamin d2 compounds
NZ555561A (en) 2004-11-22 2009-02-28 Wisconsin Alumni Res Found 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol (a Vitamin D derivative)
JP2008520708A (ja) * 2004-11-22 2008-06-19 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１９−ノル−（２０Ｒ）−１α−ヒドロキシ−ビスホモプレグナカルシフェロール
NZ555563A (en) * 2004-11-22 2009-02-28 Wisconsin Alumni Res Found 2-methylene-19-nor-(20S)-1alpha-hydroxy-trishomopregnacalciferol
WO2006057899A2 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses
EP2240439B1 (en) * 2007-12-28 2015-03-18 Wisconsin Alumni Research Foundation (20s)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs
JP2011508744A (ja) * 2007-12-28 2011-03-17 ウィスコンシン アラムナイ リサーチ ファンデーション （２０ｒ）−２３，２３−ジフルオロ−２−メチレン−１９−ノル−ビスホモプレグナカルシフェロール−ビタミンｄ類縁体

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0503923B1 (en) * 1991-03-11 1994-12-28 Wisconsin Alumni Research Foundation Synthesis of 1 alpha-hydroxy-secosterol compounds
WO1998041501A1 (en) * 1997-03-17 1998-09-24 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin d compounds
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
WO2002020021A1 (en) * 2000-09-08 2002-03-14 Wisconsin Alumni Research Foundation 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
WO2003051828A2 (en) * 2001-12-13 2003-06-26 Wisconsin Alumni Research Foundation (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6566352B1 (en) * 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
WO2003075932A1 (en) * 2002-02-18 2003-09-18 Wisconsin Alumni Research Foundation 1-alpha-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
WO2005051323A2 (en) * 2003-11-25 2005-06-09 Wisconsin Alumni Research Foundation Vitamin d analogs for obesity prevention and treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLUM LORI A et al. Proceedings of the National Academy of Sciences of USA, (2004), vol. 101 (18), pp. 6900-6904. *

Also Published As

Publication number Publication date
WO2006057915A2 (en) 2006-06-01
NZ555561A (en) 2009-02-28
AU2005309820A1 (en) 2006-06-01
CA2588063C (en) 2012-10-16
US20060135800A1 (en) 2006-06-22
JP5036548B2 (ja) 2012-09-26
ATE499942T1 (de) 2011-03-15
DE602005026694D1 (de) 2011-04-14
EP1827452A4 (en) 2009-10-21
CA2588063A1 (en) 2006-06-01
EP1827452A2 (en) 2007-09-05
US8604008B2 (en) 2013-12-10
MX2007006094A (es) 2007-07-11
ES2358914T3 (es) 2011-05-16
WO2006057915A3 (en) 2006-07-13
JP2008520710A (ja) 2008-06-19
EP1827452B1 (en) 2011-03-02

Similar Documents

Publication Publication Date Title
US7648973B2 (en) 2-methylene-1α,25-dihydroxy-19,21-dinorvitamin D3 analogs and uses thereof
US7563783B2 (en) 2-methylene-19-nor-(20S-24S)-1α,25-dihydroxyvitamin-D2
US7541348B2 (en) 2-methylene-19-nor-(20S)-1α-hydroxy-trishomopregnacalciferol
US8222235B2 (en) 2-methylene-19-nor-(20R)-1α-hydroxy-bishomopregnacalciferol
AU2006213722B2 (en) 2-methylene-19-nor-(20S-24epi)-1alpha,25-dihydroxyvitamin-D2
AU2005309820B2 (en) 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired